OBJECTIVES: Monocytes include several subsets with different and sometimes divergent roles in immunity, @entity731 and reparative processes. OBJECTIVES: We aimed to perform detailed immunophenotypic and functional characterization of @entity1 monocyte subsets. @entity1 /METHODS: Analysis of surface markers of blood and bone marrow monocyte subsets and functional characterization of blood monocyte subsets in healthy volunteers was performed using flow cytometry. RESULTS: In the present study, we show the presence of three subsets which could be unequivocally distinguished by surface expression of @entity5750 , @entity4071 and @entity9172 as @entity5750 (+) @entity4071 (-) @entity9172 (+) (Mon1), @entity5750 (+) @entity4071 (+) @entity9172 (+) ( @entity30641 ) and @entity5750 (low) @entity4071 (+) @entity9172 (-) (Mon3) subsets. In comparison with the classic Mon1, the @entity30641 subset had the highest expression of @entity878 , @entity436 , @entity11772 , @entity6823 , receptors to @entity2071 ( @entity2071 ), @entity7 ( @entity7 ), and the highest surface levels of @entity755 and ferritin. In contrast, Mon3 had maximal expression of @entity4725 receptors and @entity13242 . The @entity30641 and Mon3 subsets had significantly lower activity of the NFkB pathway than Mon1. Mon1 and @entity30641 had similar phagocytic activity, which was significantly higher compared with Mon3. All three subsets were present in bone marrow, although the relative proportion of @entity30641 in bone marrow was about 2.5-fold higher compared with that seen in blood. Significant differences in cytokine production in response to endotoxin stimulation were observed between the three monocyte subsets. CONCLUSION: Given their immunophenotypic similarity, the newly characterized @entity30641 population may represent the previously reported pluripotent progenitor/pro-angiogenic monocytes.

Immunophenotypic characterization of XXXX monocyte subsets: possible implications for cardiovascular disease pathophysiology.

@entity1 :: ('9606', 'Species') :: ['human', 'PATIENTS'] @entity878 :: ('7010', 'Gene') :: ['Tie2'] @entity9172 :: ('729230', 'Gene') :: ['CCR2'] @entity4725 :: ('7412', 'Gene') :: ['VCAM-1'] @entity5750 :: ('929', 'Gene') :: ['CD14'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity6823 :: ('1436', 'Gene') :: ['CD115'] @entity13242 :: ('4481', 'Gene') :: ['CD204'] @entity755 :: ('338', 'Gene') :: ['apolipoprotein B'] @entity11772 :: ('9332', 'Gene') :: ['CD163'] @entity4071 :: ('2214', 'Gene') :: ['CD16'] @entity2071 :: ('3383', 'Gene') :: ['ICAM-1', 'inter-cellular adhesion molecule-1'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherogenesis'] @entity30641 :: ('23041', 'Gene') :: ['Mon2'] @entity436 :: ('7852', 'Gene') :: ['CXCR4']
@entity1 :: (9606,Species) :: ['human']
